A shift in paradigm towards human biology‐based systems for cholestatic‐liver diseases

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Physiology

• Publication date

  2015-12-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1113/JP271124PMID 26417843PMCID PMC4666998
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In Silico Modeling for the Prediction of Dose and Pathway-Related Adverse Effects in Humans From In Vitro Repeated-Dose Studies.

  2016cited by this paper
• Functional human induced hepatocytes (hiHeps) with bile acid synthesis and transport capacities: A novel in vitro cholestatic model

  2016cited by this paper
• Are adverse outcome pathways here to stay?

  2015cited by this paper
• Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.

  2015cited by this paper
• Epidemiology of cholangiocarcinoma.

  2015cited by this paper
• Bile acids as metabolic regulators

  2015cited by this paper
• Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis.

  2015cited by this paper
• Bile proteome in health and disease.

  2014cited by this paper
• The human microbiome and bile acid metabolism: dysbiosis, dysmetabolism, disease and intervention

  2014cited by this paper
• Adverse outcome pathway (AOP) development I: strategies and principles.

  2014cited by this paper
• High Throughput Micro-Well Generation of Hepatocyte Micro-Aggregates for Tissue Engineering

  2014cited by this paper
• Modeling human development and disease in pluripotent stem cell-derived gastric organoids

  2014cited by this paper
• Microbiome: The bacterial tightrope

  2014cited by this paper
• High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statins

  2014cited by this paper
• Pathway-based toxicity: history, current approaches and liver fibrosis and steatosis as prototypes.

  2014cited by this paper
• The Burden of Gastrointestinal and Liver Disease Around the World

  2014cited by this paper
• Competency of different cell models to predict human hepatotoxic drugs

  2014cited by this paper
• The 3D printing of gelatin methacrylamide cell-laden tissue-engineered constructs with high cell viability.

  2014cited by this paper
• Pluripotent stem cell-derived hepatocyte-like cells.

  2014cited by this paper
• Adverse outcome pathway development II: best practices.

  2014cited by this paper
• Pathways of Toxicity.

  2014cited by this paper
• High-Content Assays for Hepatotoxicity Using Induced Pluripotent Stem Cell–Derived Cells

  2014cited by this paper
• Bile proteomics for differentiation of malignant from benign biliary strictures: a pilot study

  2014cited by this paper
• Is animal research sufficiently evidence based to be a cornerstone of biomedical research?

  2014cited by this paper
• A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies

  2014cited by this paper
• Chronic cholestatic liver diseases: clues from histopathology for pathogenesis.

  2014cited by this paper
• Role of the microbiome in energy regulation and metabolism.

  2014cited by this paper
• In vitro platforms for evaluating liver toxicity

  2014cited by this paper
• Microfluidic organs-on-chips

  2014cited by this paper
• 3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies.

  2014cited by this paper
• Adverse Outcome Pathway-based Screening Strategies for an Animal-free Safety Assessment of Chemicals

  2013cited by this paper
• Epigenomic regulation of bile acid metabolism: emerging role of transcriptional cofactors.

  2013cited by this paper
• The metabolomic window into hepatobiliary disease.

  2013cited by this paper
• Novel insights into autoimmune liver diseases provided by genome-wide association studies.

  2013cited by this paper
• Metabolomics in toxicology and preclinical research.

  2013cited by this paper
• Animal models of chronic liver diseases.

  2013cited by this paper
• Bile acid transporters and regulatory nuclear receptors in the liver and beyond

  2013cited by this paper
• Modelling human disease with pluripotent stem cells.

  2013cited by this paper
• Use and validation of HT/HC assays to support 21st century toxicity evaluations.

  2013cited by this paper
• Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid.

  2013cited by this paper
• 3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies.

  2013cited by this paper
• Identification of a primary biliary cirrhosis associated protein as lysosome-associated membrane protein-2.

  2013cited by this paper
• Intestinal dendritic cells: their role in intestinal inflammation, manipulation by the gut microbiota and differences between mice and men.

  2013cited by this paper
• Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury.

  2013cited by this paper
• Genomic responses in mouse models poorly mimic human inflammatory diseases

  2013cited by this paper
• Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME

  2013cited by this paper
• Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study.

  2012cited by this paper
• Features, diagnosis, and treatment of nonalcoholic fatty liver disease.

  2012cited by this paper
• Isotope labeling experiments in metabolomics and fluxomics

  2012cited by this paper
• Animal models of biliary tract injury

  2012cited by this paper
• Biotransformation of diclofenac and effects on the metabolome of primary human hepatocytes upon repeated dose exposure.

  2012cited by this paper
• Transcription factors controlling responses to toxic chemicals

  2012cited by this paper
• Effect of bile duct ligation on bile acid composition in mouse serum and liver

  2012cited by this paper
• An Update on Genetic Analysis of Cholestatic Liver Diseases: Digging Deeper

  2011cited by this paper
• Further Characterization of the Electrogenicity and pH Sensitivity of the Human Organic Anion-Transporting Polypeptides OATP1B1 and OATP1B3

  2011cited by this paper
• Histone H3K4 trimethylation by MLL3 as part of ASCOM complex is critical for NR activation of bile acid transporter genes and is downregulated in cholestasis.

  2011cited by this paper
• Pathological Features of New Animal Models for Primary Biliary Cirrhosis

  2011influential reference
• Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis

  2011cited by this paper
• Ecological physiology of diet and digestive systems.

  2011cited by this paper
• Human immunology: a case for the ascent of non‐furry immunology

  2011cited by this paper
• Generation of Liver Disease-Specific Induced Pluripotent Stem Cells Along with Efficient Differentiation to Functional Hepatocyte-Like Cells

  2010cited by this paper
• Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human.

  2010cited by this paper
• Induced pluripotent stem cells: a new era for hepatology.

  2010cited by this paper
• Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment

  2010cited by this paper
• Secretory IgA: Arresting Microbial Pathogens at Epithelial Borders

  2010cited by this paper
• Murine models of autoimmune cholangitis

  2010cited by this paper
• Genome-wide association studies and genetic risk assessment of liver diseases

  2010cited by this paper
• Nuclear receptors as therapeutic targets in cholestatic liver diseases

  2009cited by this paper
• Role of bile acids and bile acid receptors in metabolic regulation.

  2009cited by this paper
• Bile acids and insulin resistance: implications for treating nonalcoholic fatty liver disease

  2009cited by this paper
• Microscale culture of human liver cells for drug development

  2008cited by this paper
• Endocrine and paracrine role of bile acids.

  2008cited by this paper
• HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in Humans

  2008cited by this paper
• Bile Acids: Chemistry, Pathochemistry, Biology, Pathobiology, and Therapeutics

  2008cited by this paper
• Targeting bile-acid signalling for metabolic diseases

  2008cited by this paper
• Pathobiology of biliary epithelia and cholangiocarcinoma: Proceedings of the Henry M. and Lillian Stratton basic research single‐topic conference

  2008cited by this paper
• Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies

  2008cited by this paper
• Lithocholic acid derivatives act as selective vitamin D receptor modulators without inducing hypercalcemia Published, JLR Papers in Press, January 7, 2008.

  2008cited by this paper
• The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.

  2007cited by this paper
• Inter-species transplantation of gut microbiota from human to pigs

  2007cited by this paper
• Differential Inhibition of Rat and Human Na+-Dependent Taurocholate Cotransporting Polypeptide (NTCP/SLC10A1)by Bosentan: A Mechanism for Species Differences in Hepatotoxicity

  2007cited by this paper
• Cell shape regulates global histone acetylation in human mammary epithelial cells.

  2007cited by this paper
• Endocrine functions of bile acids

  2006cited by this paper
• Extracellular matrix, nuclear and chromatin structure, and gene expression in normal tissues and malignant tumors: a work in progress.

  2006cited by this paper
• Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation

  2006cited by this paper
• Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction

  2006cited by this paper
• The Burden of Gastrointestinal and Liver Diseases, 2006

  2006cited by this paper
• Global challenges in liver disease

  2006cited by this paper
• Anti-Mitochondrial Antibodies and Primary Biliary Cirrhosis in TGF-β Receptor II Dominant-Negative Mice1

  2006cited by this paper
• Extracellular Matrix-regulated Gene Expression Requires Cooperation of SWI/SNF and Transcription Factors*

  2006cited by this paper
• Mechanism of Growth Inhibition by Free Bile Acids in Lactobacilli and Bifidobacteria

  2006cited by this paper
• The interaction between bacteria and bile.

  2005cited by this paper
• Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis

  2005influential reference
• Outcome and prognostic markers in severe drug‐induced liver disease

  2005cited by this paper
• Bile acid transport in sister of P-glycoprotein (ABCB11) knockout mice.

  2005cited by this paper
• Activation of signalling pathways during hepatocyte isolation: relevance to toxicology in vitro.

  2004cited by this paper
• Metabolomics – the link between genotypes and phenotypes

  2004cited by this paper
• Germline epimutation of MLH1 in individuals with multiple cancers

  2004cited by this paper
• Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment.

  2004cited by this paper
• The epidemiology of cholangiocarcinoma.

  2004cited by this paper

• Population pharmacokinetic model to generate mechanistic insights in bile acid homeostasis and drug-induced cholestasis

  2022cites this paper
• Hepatic bile acid synthesis and secretion: comparison of in vitro methods.

  2022cites this paper
• Development of an adverse outcome pathway for intrahepatic cholestasis of pregnancy

  2022cites this paper
• Rodent models of cholestatic liver disease: A practical guide for translational research

  2021cites this paper
• Application of microphysiological systems in biopharmaceutical research and development.

  2020cites this paper
• Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury

  2020cites this paper
• Metformin Disrupts Bile Acid Efflux by Repressing Bile Salt Export Pump Expression

  2020cites this paper
• Industrial, Biocide, and Cosmetic Chemical Inducers of Cholestasis.

  2019cites this paper
• Primary hepatocytes and their cultures for the testing of drug-induced liver injury.

  2019cites this paper
• Mechanisms and in vitro models of drug-induced cholestasis

  2019cites this paper
• The Changing Paradigm in Preclinical Toxicology: in vitro and in silico Methods in Liver Toxicity Evaluations

  2019cites this paper
• Prediction of Human Liver Toxicity Using In Vitro Assays: Limitations and Opportunities

  2018cites this paper
• Human-specific approaches to brain research for the 21st century: a South American perspective.

  2018cites this paper
• In vitro prediction of drug-induced cholestatic liver injury: a challenge for the toxicologist

  2018influential citation
• Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations.

  2017cites this paper
• Functional human induced hepatocytes (hiHeps) with bile acid synthesis and transport capacities: A novel in vitro cholestatic model

  2016cites this paper